** Shares of biotechnology company Immutep IMM.AX rise as much as 2.2% to A$0.348, their highest since Nov. 14
** Co has announced initiation of phase-3 trial for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC)
** Says trial will include over 150 clinical sites in over 25 countries
** Co expects to enrol the first patient in Q1 of CY2025.
** Stock has fallen 0.5% YTD, as of last close
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.